Dr. Elie G. Dib
Claim this profileGenesys Hurley Cancer Institute
Studies Multiple Myeloma
Studies Breast Cancer
38 reported clinical trials
105 drugs studied
Area of expertise
1Multiple Myeloma
Stage I
Stage II
Stage III
2Breast Cancer
HER2 negative
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Elie G. Dib is currently running
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
More about Elie G. Dib
Clinical Trial Related6 years of experience running clinical trials · Led 38 trials as a Principal Investigator · 19 Active Clinical TrialsTreatments Elie G. Dib has experience with
- Nivolumab
- Lenalidomide
- Dexamethasone
- Atezolizumab
- Durvalumab
- Pembrolizumab
Breakdown of trials Elie G. Dib has run
Multiple Myeloma
Breast Cancer
Cancer
Breast cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Elie G. Dib specialize in?
Elie G. Dib focuses on Multiple Myeloma and Breast Cancer. In particular, much of their work with Multiple Myeloma has involved Stage I patients, or patients who are Stage II.
Is Elie G. Dib currently recruiting for clinical trials?
Yes, Elie G. Dib is currently recruiting for 19 clinical trials in Flint Michigan. If you're interested in participating, you should apply.
Are there any treatments that Elie G. Dib has studied deeply?
Yes, Elie G. Dib has studied treatments such as Nivolumab, Lenalidomide, Dexamethasone.
What is the best way to schedule an appointment with Elie G. Dib?
Apply for one of the trials that Elie G. Dib is conducting.
What is the office address of Elie G. Dib?
The office of Elie G. Dib is located at: Genesys Hurley Cancer Institute, Flint, Michigan 48503 United States. This is the address for their practice at the Genesys Hurley Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.